Major treatment-based adverse events
| Parameter | Treatment (No. of patients) | |
|---|---|---|
| RP (n = 73) % | P (n = 75) % | |
| Grade 3-4 adverse events | 36.2 | 28.2 |
| Grade 3-4 neutropenia | 11.0 | 4.0 |
| Grade 3-4 anemia | 1.4 | 4.0 |
| Grade 3-4 thrombocytopenia | 1.4 | 5.3 |
| All grades of peripheral neurotoxicity | 12.3 | 17.3 |
| All grades of hepatic toxicity based on elevated aminotransferase levels | 27.4 | 14.1 |
RP, raltitrexed plus paclitaxel; P, paclitaxel.